Oasmia Pharmaceu Ads (OASM) 3.20 $OASM
Interim report for the period May - July 2016
GlobeNewswire - Fri Sep 02, 8:36AM CDT
FIRST QUARTER May 1 - July 31, 2016
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Appoints Fredrik Gynnerstedt as Chief Financial Officer
GlobeNewswire - Wed Aug 31, 6:05AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology has announced the appointment of Fredrik Gynnerstedt to the position of Chief Financial Officer (CFO).
OASM: 3.20 (-0.16)
Oasmia successfully completes a private placement of new convertible instruments in a total amount of SEK 42,000,000
GlobeNewswire - Fri Jun 10, 6:20AM CDT
The Private Placement has enabled Oasmia to place 42 new convertible instruments with a limited group of investors identified by Stockholm Corporate Finance AB at a nominal value of SEK 1,000,000 per convertible instrument through an accelerated book building procedure.
OASM: 3.20 (-0.16)
Year-end report for the fiscal year May 1, 2015 - April 30, 2016
GlobeNewswire - Fri Jun 03, 6:26AM CDT
FOURTH QUARTER February 1 - April 30, 2016
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical to Identify International Partners for Marketing, Distribution and new Product Development based on the Company's Nanotechnology XR17
GlobeNewswire - Thu May 26, 6:12AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced its intent to identify international marketing, distribution, and development partners to facilitate entry into a number of key markets following anticipated but pending approval from regulatory bodies in Europe (EMA), the United States (FDA), and other regions throughout the world.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer
GlobeNewswire - Wed Apr 27, 6:27AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial ovarian cancer. These preliminary results showed non-inferiority between the two treatment groups of Paclical/Apealea in combination with carboplatin versus Taxol in combination with carboplatin. In fact, the overall survival in patients completing 6 treatment cycles was 25.7 months in patients that had received the Paclical/Apealea combination compared to 24.8 months in patients that had received the Taxol combination.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer
PR Newswire - Wed Apr 27, 6:00AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial ovarian cancer. These preliminary results showed non-inferiority between the two treatment groups: Paclical/Apealea in combination with carboplatin versus Taxol in combination with carboplatin. In fact, the overall survival in patients completing 6 treatment cycles was 25.7 months in patients that had received the Paclical/Apealea combination compared to 24.8 months in patients that had received the Taxol combination.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB (Nasdaq: OASM) to Ring the Nasdaq Stock Market Opening Bell on January 11
GlobeNewswire - Mon Jan 11, 6:33AM CST
Oasmia Pharmaceutical AB (Nasdaq:OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced that the Company will ring the Nasdaq Opening Bell on Monday, January 11 in honor of its recent listing on the Nasdaq Capital Market.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical to Ring the Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Jan 08, 9:00AM CST
What:
OASM: 3.20 (-0.16), NDAQ: 70.67 (+1.05)
Oasmia Submits Application for Market Approval of its Next Generation Anti-Cancer Drug Doxophos(r) in Russia
GlobeNewswire - Mon Jan 04, 6:06AM CST
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has submitted an application for marketing approval of Doxophos for Russia and the Commonwealth of the Independent States (CIS). The Company expects market approval of Doxophos by the end of 2016.
JNJ: 118.91 (+0.96), OASM: 3.20 (-0.16)
Oasmia Pharmaceutical's Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials
GlobeNewswire - Mon Dec 07, 6:05AM CST
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that its next anti-cancer drug Docecal, has been approved for clinical clients and patient recruitment will commence in January 2016.
OASM: 3.20 (-0.16)
Interim report for the period May - October 2015
GlobeNewswire - Thu Dec 03, 6:07AM CST
SECOND QUARTER August 1 - October 31, 2015
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical's Lead Human Cancer Drug Paclical(r) Generates Strong Interest at the 19th Annual Russian Cancer Congress
GlobeNewswire - Fri Nov 20, 6:07AM CST
Oasmia Pharmaceutical AB (NASDAQ:OASM), or the "Company," a developer of a new generation of drugs within human and veterinary oncology, recently presented clinical data at the 19 annual Russian Cancer Congress that illustrate the efficacy and benefits of the Company's recently approved cancer drug Paclical. The data, which were presented by Russian lead oncologists Professor Tjulandin and Dr. Chekini, were well received by the many oncologists in attendance at the event, positioning the drug for further growth in the Russian market.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Announces an Additional and Partial Exercise of Over-Allotment
GlobeNewswire - Thu Nov 05, 10:40AM CST
Oasmia Pharmaceutical AB (NASDAQ:OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the "Company"
. Oasmia's product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical(r) From Head-to-Head Comparison Study with Abraxane(r)
GlobeNewswire - Thu Nov 05, 6:05AM CST
Oasmia Pharmaceutical AB (NASDAQ:OASM), a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®
PR Newswire - Thu Nov 05, 6:00AM CST
Final analysis of the pharmacokinetic study confirms that water soluble and solvent free Paclical and US-market approved Abraxane have nearly identical concentration curves of both total and unbound paclitaxel following intravenous infusion of 260mg/m2 suggesting the same efficacy of the two drugs
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical receives order of $7.5 million in end-user value for the Russian market
GlobeNewswire - Fri Oct 30, 6:06AM CDT
Oasmia Pharmaceutical AB (NASDAQ:OASM) - a developer of a new generation of drugs within human and veterinary oncology, announced today that it its distribution partner in Russia and the Commonwealth of Independent States, CIS, Pharmasyntez, has placed its second order for Paclical, Oasmia's lead cancer product for an end user sale value of $7.5 million. The announcement comes on the heels of the first order to the Russia market for $1.5 million in end-user value, totaling an end-user sales value of over $9 million USD in commercial orders within one week.
SE: 42.67 (+0.67), OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing
GlobeNewswire - Thu Oct 29, 6:16AM CDT
Oasmia Pharmaceutical AB (NASDAQ:OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the "Company". Oasmia's product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. Oasmia announce the closing of a U.S. underwritten public offering of American Depositary Shares, or ADSs, and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price of $4.06 per ADS and $0.0025 per warrant. Each ADS represents three of Oasmia's ordinary shares. The Company received gross proceeds of approximately $9,500,354 from the initial securities sold in this offering, before deducting underwriting discounts, commissions and other related expenses. The warrants have an exercise price of $4.06, are exercisable immediately and will expire ten years from the date of issuance. The Company granted the underwriters a 45-day option to purchase up to (i) 350,880 additional ADSs and/or (ii) additional warrants to purchase up to 175,440 ADSs to cover over-allotments. The underwriters have exercised an option to purchase 111,150 such additional warrants, which transaction closed on October 28, 2015.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical for the Russian market
GlobeNewswire - Wed Oct 28, 7:15AM CDT
Oasmia Pharmaceutical AB ("Oasmia" or the "Company", a developer of a new generation of drugs within human and veterinary oncology, announced today that it its distribution partner, Pharmasyntez, has executed the first order of Paclical, Oasmia's lead cancer product. Paclical, a novel water-soluble formulation of paclitaxel, was approved in April, 2015 and shipped earlier for commercial sampling purposes. While this announcement will result in the first commercial sales shipment later this quarter, Oasmia expects additional sales announcements.
OASM: 3.20 (-0.16)
Interim report for the period May - July 2016
GlobeNewswire - Fri Sep 02, 8:36AM CDT
FIRST QUARTER May 1 - July 31, 2016
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Appoints Fredrik Gynnerstedt as Chief Financial Officer
GlobeNewswire - Wed Aug 31, 6:05AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology has announced the appointment of Fredrik Gynnerstedt to the position of Chief Financial Officer (CFO).
OASM: 3.20 (-0.16)
Oasmia successfully completes a private placement of new convertible instruments in a total amount of SEK 42,000,000
GlobeNewswire - Fri Jun 10, 6:20AM CDT
The Private Placement has enabled Oasmia to place 42 new convertible instruments with a limited group of investors identified by Stockholm Corporate Finance AB at a nominal value of SEK 1,000,000 per convertible instrument through an accelerated book building procedure.
OASM: 3.20 (-0.16)
Year-end report for the fiscal year May 1, 2015 - April 30, 2016
GlobeNewswire - Fri Jun 03, 6:26AM CDT
FOURTH QUARTER February 1 - April 30, 2016
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical to Identify International Partners for Marketing, Distribution and new Product Development based on the Company's Nanotechnology XR17
GlobeNewswire - Thu May 26, 6:12AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced its intent to identify international marketing, distribution, and development partners to facilitate entry into a number of key markets following anticipated but pending approval from regulatory bodies in Europe (EMA), the United States (FDA), and other regions throughout the world.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer
GlobeNewswire - Wed Apr 27, 6:27AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial ovarian cancer. These preliminary results showed non-inferiority between the two treatment groups of Paclical/Apealea in combination with carboplatin versus Taxol in combination with carboplatin. In fact, the overall survival in patients completing 6 treatment cycles was 25.7 months in patients that had received the Paclical/Apealea combination compared to 24.8 months in patients that had received the Taxol combination.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer
PR Newswire - Wed Apr 27, 6:00AM CDT
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced positive overall survival results for Paclical/Apealea in the Phase III study that included a total of 789 patients with epithelial ovarian cancer. These preliminary results showed non-inferiority between the two treatment groups: Paclical/Apealea in combination with carboplatin versus Taxol in combination with carboplatin. In fact, the overall survival in patients completing 6 treatment cycles was 25.7 months in patients that had received the Paclical/Apealea combination compared to 24.8 months in patients that had received the Taxol combination.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB (Nasdaq: OASM) to Ring the Nasdaq Stock Market Opening Bell on January 11
GlobeNewswire - Mon Jan 11, 6:33AM CST
Oasmia Pharmaceutical AB (Nasdaq:OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced that the Company will ring the Nasdaq Opening Bell on Monday, January 11 in honor of its recent listing on the Nasdaq Capital Market.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical to Ring the Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Jan 08, 9:00AM CST
What:
OASM: 3.20 (-0.16), NDAQ: 70.67 (+1.05)
Oasmia Submits Application for Market Approval of its Next Generation Anti-Cancer Drug Doxophos(r) in Russia
GlobeNewswire - Mon Jan 04, 6:06AM CST
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has submitted an application for marketing approval of Doxophos for Russia and the Commonwealth of the Independent States (CIS). The Company expects market approval of Doxophos by the end of 2016.
JNJ: 118.91 (+0.96), OASM: 3.20 (-0.16)
Oasmia Pharmaceutical's Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials
GlobeNewswire - Mon Dec 07, 6:05AM CST
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that its next anti-cancer drug Docecal, has been approved for clinical clients and patient recruitment will commence in January 2016.
OASM: 3.20 (-0.16)
Interim report for the period May - October 2015
GlobeNewswire - Thu Dec 03, 6:07AM CST
SECOND QUARTER August 1 - October 31, 2015
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical's Lead Human Cancer Drug Paclical(r) Generates Strong Interest at the 19th Annual Russian Cancer Congress
GlobeNewswire - Fri Nov 20, 6:07AM CST
Oasmia Pharmaceutical AB (NASDAQ:OASM), or the "Company," a developer of a new generation of drugs within human and veterinary oncology, recently presented clinical data at the 19 annual Russian Cancer Congress that illustrate the efficacy and benefits of the Company's recently approved cancer drug Paclical. The data, which were presented by Russian lead oncologists Professor Tjulandin and Dr. Chekini, were well received by the many oncologists in attendance at the event, positioning the drug for further growth in the Russian market.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Announces an Additional and Partial Exercise of Over-Allotment
GlobeNewswire - Thu Nov 05, 10:40AM CST
Oasmia Pharmaceutical AB (NASDAQ:OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the "Company"
. Oasmia's product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical(r) From Head-to-Head Comparison Study with Abraxane(r)
GlobeNewswire - Thu Nov 05, 6:05AM CST
Oasmia Pharmaceutical AB (NASDAQ:OASM), a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer.
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®
PR Newswire - Thu Nov 05, 6:00AM CST
Final analysis of the pharmacokinetic study confirms that water soluble and solvent free Paclical and US-market approved Abraxane have nearly identical concentration curves of both total and unbound paclitaxel following intravenous infusion of 260mg/m2 suggesting the same efficacy of the two drugs
OASM: 3.20 (-0.16)
Oasmia Pharmaceutical receives order of $7.5 million in end-user value for the Russian market
GlobeNewswire - Fri Oct 30, 6:06AM CDT
Oasmia Pharmaceutical AB (NASDAQ:OASM) - a developer of a new generation of drugs within human and veterinary oncology, announced today that it its distribution partner in Russia and the Commonwealth of Independent States, CIS, Pharmasyntez, has placed its second order for Paclical, Oasmia's lead cancer product for an end user sale value of $7.5 million. The announcement comes on the heels of the first order to the Russia market for $1.5 million in end-user value, totaling an end-user sales value of over $9 million USD in commercial orders within one week.
SE: 42.67 (+0.67), OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing
GlobeNewswire - Thu Oct 29, 6:16AM CDT
Oasmia Pharmaceutical AB (NASDAQ:OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the "Company"
. Oasmia's product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. Oasmia announce the closing of a U.S. underwritten public offering of American Depositary Shares, or ADSs, and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price of $4.06 per ADS and $0.0025 per warrant. Each ADS represents three of Oasmia's ordinary shares. The Company received gross proceeds of approximately $9,500,354 from the initial securities sold in this offering, before deducting underwriting discounts, commissions and other related expenses. The warrants have an exercise price of $4.06, are exercisable immediately and will expire ten years from the date of issuance. The Company granted the underwriters a 45-day option to purchase up to (i) 350,880 additional ADSs and/or (ii) additional warrants to purchase up to 175,440 ADSs to cover over-allotments. The underwriters have exercised an option to purchase 111,150 such additional warrants, which transaction closed on October 28, 2015. OASM: 3.20 (-0.16)
Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical for the Russian market
GlobeNewswire - Wed Oct 28, 7:15AM CDT
Oasmia Pharmaceutical AB ("Oasmia" or the "Company"
, a developer of a new generation of drugs within human and veterinary oncology, announced today that it its distribution partner, Pharmasyntez, has executed the first order of Paclical, Oasmia's lead cancer product. Paclical, a novel water-soluble formulation of paclitaxel, was approved in April, 2015 and shipped earlier for commercial sampling purposes. While this announcement will result in the first commercial sales shipment later this quarter, Oasmia expects additional sales announcements. OASM: 3.20 (-0.16)
